Noninvasive, medical management for non-ST-elevation acute coronary syndromes

American Heart Journal

Volumn 155, Issue 3, 2008, Pages 397-407

  Chan, Mark Y ^a   Becker, Richard C ^a   Harrington, Robert A ^a   Peterson, Eric D ^a   Armstrong, Paul W ^b   White, Harvey ^c   Fox, Keith A A ^d   Ohman, E Magnus ^a   Roe, Matthew T ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FONDAPARINUX; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; PERINDOPRIL; PRAVASTATIN; THIENOPYRIDINE DERIVATIVE; VALSARTAN; WARFARIN;

ACUTE CORONARY SYNDROME; BLEEDING; CLINICAL TRIAL; HEART CATHETERIZATION; HEART MUSCLE REVASCULARIZATION; HUMAN; NON INVASIVE PROCEDURE; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; REVIEW; ST SEGMENT;

ACUTE DISEASE; CORONARY ANGIOGRAPHY; CORONARY DISEASE; ELECTROCARDIOGRAPHY; HEART CATHETERIZATION; HUMANS; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 39249084060     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.11.014     Document Type: Review

References (59)

1. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol 50 (2007) e1-e157
2. Bassand J.P., Hamm C.W., Ardissino D., et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28 (2007) 1598-1660
3. Fox K.A., Anderson Jr. F.A., Dabbous O.H., et al. Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE). Heart 93 (2007) 177-182
4. Carruthers K.F., Dabbous O.H., Flather M.D., et al. Contemporary management of acute coronary syndromes: does the practice match the evidence? The global registry of acute coronary events (GRACE). Heart 91 (2005) 290-298
5. Kandzari D.E., Roe M.T., Chen A.Y., et al. Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes. Am Heart J 149 (2005) 474-481
6. Fox K.A., Poole-Wilson P.A., Henderson R.A., et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial, Randomized Intervention Trial of unstable Angina. Lancet 360 (2002) 743-751
7. Cannon C.P., Weintraub W.S., and Dempoulos L.A. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 344 (2001) 1879-1887
8. Fox K.A., Steg P.G., Eagle K.A., et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 297 (2007) 1892-1900
9. Roe M.T., Parsons L.S., Pollack Jr. C.V., et al. Quality of care by classification of myocardial infarction: treatment patterns for ST-segment elevation vs non-ST-segment elevation myocardial infarction. Arch Intern Med 165 (2005) 1630-1636
10. Tricoci P., Roe M.T., Mulgund J., et al. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. Arch Intern Med 166 (2006) 806-811
11. Mandelzweig L., Battler A., Boyko V., et al. The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J 27 (2006) 2285-2293
12. Yusuf S., Mehta S.R., Chrolavicius S., et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 (2006) 1464-1476
13. Blazing M.A., de Lemos J.A., White H.D., et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 292 (2004) 55-64
14. Yusuf S., Mehta S.R., Zhao F., et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 107 (2003) 966-972
15. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 339 (1998) 436-443
16. Goodman S.G., Cohen M., Bigonzi F., et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol 36 (2000) 693-698
17. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 335 (1996) 775-782
18. Roe M.T., Peterson E.D., Newby L.K., et al. The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes. Am Heart J 151 (2006) 1205-1213
19. Mehta R.H., Peterson E.D., Liang L., et al. Contraindications to cardiac catheterization in non-ST-elevation acute coronary syndromes: insights from the CRUSADE national quality improvement initiative. Eur Heart J 27 (2006) S1-S183
20. Stukel T.A., Lucas F.L., and Wennberg D.E. Long-term outcomes of regional variations in intensity of invasive vs medical management of Medicare Patients with acute myocardial infarction. JAMA 293 (2005) 1329-1337
21. Blomkalns A.L., Chen A.Y., Hochman J.S., et al. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) national quality improvement initiative. J Am Coll Cardiol 45 (2005) 832-837
22. Sonel A.F., Good C.B., Mulgund J., et al. Racial variations in treatment and outcomes of black and white patients with high-risk non-ST-elevation acute coronary syndromes: insights from CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines?). Circulation 111 (2005) 1225-1232
23. Roe M.T., Chen A.Y., Riba A.L., et al. Impact of congestive heart failure in patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol 97 (2006) 1707-1712
24. Han J.H., Chandra A., Mulgund J., et al. Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. Am J Med 119 (2006) 248-254
25. Haim M., Battler A., Behar S., et al. Acute coronary syndromes complicated by symptomatic and asymptomatic heart failure: does current treatment comply with guidelines?. Am Heart J 147 (2004) 859-864
26. Avezum A., Makdisse M., Spencer F., et al. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 149 (2005) 67-73
27. Rao S.V., Kaul P., Newby L.K., et al. Poverty, process of care, and outcome in acute coronary syndromes. J Am Coll Cardiol 41 (2003) 1948-1954
28. Pilote L., Joseph L., Belisle P., et al. Universal health insurance coverage does not eliminate inequities in access to cardiac procedures after acute myocardial infarction. Am Heart J 146 (2003) 1030-1037
29. Bugiardini R., Manfrini O., and De Ferrari G.M. Unanswered questions for management of acute coronary syndrome: risk stratification of patients with minimal disease or normal findings on coronary angiography. Arch Intern Med 166 (2006) 1391-1395
30. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction results of the TIMI IIIB trial. Circulation 89 (1994) 1545-1556
31. McCullough P.A., O'Neill W.W., Graham M., et al. A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy. Results of the medicine versus angiography in thrombolytic exclusion (MATE) trial. J Am Coll Cardiol 32 (1998) 596-605
32. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 354 (1999) 708-715
33. Fox K.A., Poole-Wilson P., Clayton T.C., et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet 366 (2005) 914-920
34. Roe M.T., Harrington R.A., Prosper D.M., et al. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Circulation 102 (2000) 1101-1106
35. Gogo Jr. P.B., Dauerman H.L., Mulgund J., et al. Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE quality improvement initiative). Am J Cardiol 99 (2007) 1222-1226
36. Bhatt D.L., Roe M.T., Peterson E.D., et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE quality improvement initiative. JAMA 292 (2004) 2096-2104
37. Erne P., Schoenenberger A.W., Burckhardt D., et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAM 297 (2007) 1985-1991
38. Budaj A., Brieger D., Steg P.G., et al. Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 146 (2003) 999-1006
39. Steinberg B.A., Steg P.G., Bhatt D.L., et al. Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry). Am J Cardiol 99 (2007) 1212-1215
40. Roe MT, Chen AY, Mehta RH, et al. Influence of inpatient service specialty on care processes and outcomes for patients with non ST-segment elevation acute coronary syndromes. 2007;116:1153-1161.
41. Miller K.L., Pollack Jr. C.V., and Peterson E.D. Moving from evidence to practice in the care of patients who have acute coronary syndrome. Cardiol Clin 24 (2006) 87-102
42. Mehta S.R., Cannon C.P., Fox K.A., et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 293 (2005) 2908-2917
43. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
44. Cattaneo M. P2Y12 receptor antagonists: a rapidly expanding group of antiplatelet agents. Eur Heart J 27 (2006) 1010-1012
45. Hurlen M., Abdelnoor M., Smith P., et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 347 (2002) 969-974
46. van Es R.F., Jonker J.J., Verheugt F.W., et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 360 (2002) 109-113
47. Andreotti F., Testa L., Biondi-Zoccai G.G., et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 27 (2006) 519-526
48. Grudy S.I., Cleeman J.I., and Bairey Merz N. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
49. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
50. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
51. Pedersen T.R., Faergeman O., Kastelein J.J., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294 (2005) 2437-2445
52. Freemantle N., Cleland J., Young P., et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 318 (1999) 1730-1737
53. Chen Z.M., Pan H.C., Chen Y.P., et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1622-1632
54. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357 (2001) 1385-1390
55. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 97 (1998) 2202-2212
56. Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 166 (2006) 659-666
57. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
58. Alexander K.P., Chen A.Y., Roe M.T., et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294 (2005) 3108-3116
59. Boden W.E., O'Rourke R.A., and Teo K.K. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356 (2007) 1503-1516